Globe Newswire (Tue, 16-Dec 8:05 AM ET)
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 13-Nov 7:20 AM ET)
Globe Newswire (Thu, 6-Nov 8:05 AM ET)
Market Chameleon (Mon, 27-Oct 4:52 AM ET)
Globe Newswire (Mon, 27-Oct 8:30 AM ET)
Globe Newswire (Tue, 14-Oct 8:30 AM ET)
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
Globe Newswire (Tue, 7-Oct 8:30 AM ET)
EMA Eligibility Paves Way for Cellectar's Iopofosine I 131 in Treating Refractory WM Across Europe
Market Chameleon (Mon, 6-Oct 4:22 AM ET)
Globe Newswire (Mon, 6-Oct 7:00 AM ET)
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Cellectar Biosciences trades on the NASDAQ stock market under the symbol CLRB.
As of December 18, 2025, CLRB stock price declined to $2.71 with 24,189 million shares trading.
CLRB has a beta of 1.57, meaning it tends to be more sensitive to market movements. CLRB has a correlation of 0.02 to the broad based SPY ETF.
CLRB has a market cap of $11.49 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CLRB traded as high as $133.50 and as low as $2.45.
The top ETF exchange traded funds that CLRB belongs to (by Net Assets): VTI, VXF.
CLRB has underperformed the market in the last year with a price return of -65.6% while the SPY ETF gained +13.1%. CLRB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -46.4% and -26.6%, respectively, while the SPY returned +2.9% and -1.1%, respectively.
CLRB support price is $2.53 and resistance is $2.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLRB shares will trade within this expected range on the day.
